California Health Watch: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on California Health Watch.

Press releases published on August 3, 2026

Aug. 3, 2026

TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI® Revenue Guidance

Indeterminate GlobeNewswire

Aug. 3, 2026

Opus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal Disease

Indeterminate GlobeNewswire

Aug. 3, 2026

Tonix Pharmaceuticals Announces Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of TNX-4800, a Human, anti-OspA Monoclonal Antibody, to Prevent Lyme Disease in the U.S.

Indeterminate GlobeNewswire

Aug. 3, 2026

Can-Fite Launches First Clinical Program for Piclidenoson in the Rare Genetic Disease Lowe Syndrome

Indeterminate GlobeNewswire

Aug. 3, 2026

Eton Pharmaceuticals to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026

Indeterminate GlobeNewswire

Aug. 3, 2026

Supernus Announces Second Quarter 2026 Financial Results

Indeterminate GlobeNewswire

Aug. 3, 2026

Indivior Reports Second Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance

Indeterminate GlobeNewswire

Aug. 3, 2026

Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale

Indeterminate GlobeNewswire

Aug. 3, 2026

BioNTech ernennt Dr. Guido Oelkers zum neuen Vorstandsvorsitzenden

Indeterminate GlobeNewswire

Aug. 3, 2026

BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer

Indeterminate GlobeNewswire

Aug. 3, 2026

Interim Results from a Clinical Study Evaluating the Impact of Virtual Lactation Support through SimpliFed on Maternal Health and Breastfeeding Success Outcomes Released at Pediatrics Academic Societies Conference

Indeterminate GlobeNewswire

Aug. 3, 2026

NRG Therapeutics Announces the Appointment of Claus Sundgreen M.D. as Chief Medical Officer

Indeterminate GlobeNewswire

Aug. 3, 2026

Aravax Awarded FDA Fast Track Designation for PVX108, a Next-Generation Immunotherapy for the Treatment of Peanut Allergy

Indeterminate GlobeNewswire

Aug. 3, 2026

Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses

Indeterminate GlobeNewswire

Aug. 3, 2026

Leads Biolabs' PD-L1/4-1BB Bispecific Antibody IND Application for Combination Therapy in Metastatic Colorectal Cancer Approved, Further Strengthening Gastrointestinal Oncology Franchise

Indeterminate GlobeNewswire